Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal International Journal of Public Health Science (IJPHS)
Zakiya Zulaifah
Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
Health Professions

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Colchicine as adjuvant therapy in COVID-19 patients: A meta-analysis Betty Rachma; Probo Yudha Pratama Putra; Zakiya Zulaifah; Arlinda Silva Prameswari; Dinda Amalia Eka Putri
International Journal of Public Health Science (IJPHS) Vol 11, No 4: December 2022
Publisher : Intelektual Pustaka Media Utama

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11591/ijphs.v11i4.21837

Abstract

SARS CoV-2 infection results in hyperinflammatory responses through the activation of proinflammatory cytokines and chemokines. Colchicine is an anti-inflammatory drug that reduces superoxide production, TNF-a activation, and neutrophil chemotaxis. This study aims to determine the effect of adjuvant colchicine on mortality in COVID-19 patients. Systematic literature searching was conducted on PubMed, ScienceDirect, Cochrane Library, and medRxiv with keywords colchicine, Coronavirus Disease, COVID-19, SARS CoV-2, and mortality. Five randomized controlled studies with 15.779 patients were included. There was no significant difference between colchicine group and standard group (OR 1.00 [95% CI 0.91-1.09], p=0.94), Invasive mechanical ventilation necessity also did not show significant difference (OR 0.99 [95% CI 0.83-1.17 p=0.88). There was no significant difference in the incidence of cardiovascular disease (OR 1.11 [95% CI 0.50-2.46], p = 0.79), also the incidence of pneumonia was lower in colchicine group (OR 0.68 [95% CI 0.49-0.93], p=0.02), while the incidence of gastrointestinal complaints was higher in colchicine group (OR 2.09 [95% CI 1.84-2.37], p<0.00001). Colchicine as COVID-19 adjuvant therapy did not significantly reduce mortality, the need for invasive mechanical ventilation, and the incidence of cardiovascular disease. Furthermore, the colchicine group had lower pneumonia incidence and higher gastrointestinal complaints incidence.
Co-Authors Arlinda Silva Prameswari Betty Rachma Dinda Amalia Eka Putri Probo Yudha Pratama Putra